Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Vectibix (panitumumab) Market Forecast: What Value Will The Market Reach By 2030?
The Vectibix (panitumumab) market has demonstrated strong expansion in recent years. Projections indicate it will advance from $1.37 million in 2025 to $1.48 million in 2026, achieving a compound annual growth rate (CAGR) of 8.0%. This growth during the historic period can be linked to its approval for metastatic colorectal cancer, proven efficacy in EGFR inhibition, widespread adoption by oncology specialists, a rise in colorectal cancer incidence, and ongoing advancements in targeted cancer drugs.
The market size for vectibix (panitumumab) is anticipated to experience substantial growth in the upcoming years, projected to reach $2 million by 2030, at a compound annual growth rate (CAGR) of 7.7%. This expansion during the forecast period can be attributed to factors such as the increasing adoption of precision medicine, improvements in cancer diagnostics, the extension into new cancer therapies, a rise in oncology healthcare spending, and refined patient stratification. Significant trends over the forecast period encompass an enhanced utilization of targeted EGFR therapies, the broadening scope of precision oncology treatments, a growing reliance on biomarker-based patient selection, the uptake of hospital-based monoclonal antibodies, and the application of combination therapy in advanced cancers.
Get A Free Sample Report With In-Depth Market Insights:
Vectibix (panitumumab) Market Growth Catalysts And Demand Drivers
The growing incidence of colorectal cancer is projected to boost the expansion of the vectibix (panitumumab) market moving forward. Colorectal cancer originates in the colon or rectum, commonly developing from precancerous polyps. The increased occurrence of colorectal cancer is attributed to unhealthy lifestyle habits, as factors like poor diet, insufficient exercise, and obesity elevate the risk of polyp formation and subsequent cancer development. Vectibix (panitumumab) operates as a monoclonal antibody designed to target and inhibit the epidermal growth factor receptor (EGFR), which helps in slowing tumor growth and progression in patients with wild-type KRAS tumors. This offers an effective therapeutic choice for those who have not responded to conventional chemotherapy. For instance, in February 2025, the American Cancer Society, a US-based nonprofit organization, estimated 154,270 new colorectal cancer cases, an increase from 152,810 cases in 2024. Therefore, the rising prevalence of colorectal cancer is anticipated to drive the growth of the vectibix (panitumumab) market.
Vectibix (panitumumab) Market Segment Performance And Emerging Opportunities
The vectibix (panitumumab) market covered in this report is segmented –
1) By Distribution Channel: Hospital Pharmacies, Online Pharmacies
2) By Application: Colorectal Cancer Treatment, Other Cancer Treatments
3) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers
Vectibix (panitumumab) Market Trends Shaping Long-Term Demand
Leading companies in the vectibix (panitumumab) market are concentrating on developing advanced companion diagnostics to facilitate targeted therapies, enhance treatment effectiveness, and ensure patient safety. Companion diagnostics are tests that provide crucial information for the safe and efficient use of a corresponding therapeutic product. As an illustration, in October 2023, EntroGen Inc., a US-based biotechnology company, obtained U.S. Food and Drug Administration (FDA) approval for its CRCdx RAS Mutation Detection Kit, designated as a companion diagnostic for Vectibix (panitumumab). The CRCdx RAS mutation detection kit is a distinct molecular diagnostic instrument that signifies a considerable leap forward in precision medicine for colorectal cancer (CRC) patients. It holds the distinction of being the first real-time PCR-based test in the U.S. to secure premarket approval (PMA) and fully meet the biomarker identification stipulation for Vectibix. This innovative kit is engineered to accurately detect mutations in KRAS and NRAS exons 2, 3, and 4, offering superior sensitivity and specificity. It allows clinicians to efficiently pinpoint patients most likely to benefit from vectibix therapy, thereby minimizing unnecessary side effects and treatment costs.
Vectibix (panitumumab) Market Key Players: Which Companies Lead Industry Competition?
Major companies operating in the vectibix (panitumumab) market are Amgen Inc.
View The Full Vectibix (panitumumab) Market Report:
Vectibix (panitumumab) Market Regional Split: Which Areas Are Fueling Growth?
North America was the largest region in the vectibix (panitumumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vectibix (panitumumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model